Aphios Announces Launch of SuperCool St. John for Emotional Well-Being, Relaxed Outlook & Positive Mood
July 13, 2004
Woburn, MA — Aphios Corporation today announced its launch of SuperCool™ St. John for mild to moderate mood swings and feelings of well-being.

SuperCool™ St. John is an advanced formulation of an enhanced hyperforin fraction of the flowers, buds and stems of St. John's Wort (Hypericum perforatum, SJW), a bushy perennial that blooms around St. John the Baptist day (June 24). Aphios' SuperCool™ St. John product is standardized against hyperforins that show a linear dose response with serotonin reuptake inhibition [US Patent No. 6,291,241B1, Castor et al., 2001]. Aphios' scientists and collaborators have shown that hyperforins are effective serotonin reuptake inhibitors (SRIs).

SuperCool™ St. John was discovered and is manufactured utilizing patented SuperFluids™ carbon dioxide technologies that are nontoxic and environmentally friendly. The product is formulated and encapsulated by Capsugel, Inc., a subsidiary of Pfizer, Inc. in accordance with cGMP (current Good Manufacturing Practices) of the United States Food and Drug Administration (FDA).

SuperCool™ St. John also contains natural Vitamin E and natural mixed tocopherols in Extra Virgin olive oil. This advanced superantioxidant formulation is designed to protect the active ingredients, hyperforins, while providing the consumers with an additional nutritional (antioxidant) benefit. This advanced formulation [US Patent Pending, 2004] also includes lecithin, an emulsifier, to increase the bioavailability of the poorly water-soluble but highly permeable hyperforins. SuperCool™ St. John is encapsulated in L-Vcaps™, liquid vegetable capsules, and does not contain any animal byproducts.

SuperCool™ St. John has not been evaluated by the FDA and is not intended to diagnose, treat, cure or prevent disease. As with any dietary supplement, consumers should consult their physician before taking this product and should be aware of contraindications when taking prescription medicines such as protease inhibitors, cyclosporine, birth control pills and antidepressants. Research leading to the development of SuperCool™ St. John was funded, in part, by the National Center for Complementary Medicine (NCCAM), National Institutes of Health (NIH).

Aphios Corporation is a biopharmaceutical company that is developing enhanced natural therapeutics for health maintenance and the treatment of human diseases with a focus on infectious diseases, oncology and CNS disorders. For more information on SuperCool™ St. John, please visit www.supercoolhealth.com.